Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Add as a preferred source on Google
Heidelberg, Germany, May 8, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on May 15, 2018, the Company will release its financial results for the quarter ended March 31, 2018. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Tuesday, May 15, 2018 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 3326332.
United States: +1 720-543-0214
Germany: +49 (0)89 20303 5709
Netherlands: +31 (0) 20 721 9251
Denmark: +45 35 15 80 49
France: +33 (0)1 76 77 22 74
Switzerland: +41 (0)22 567 5729
United Kingdom: +44 (0)330 336 9105
An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], [email protected]
